HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) and WELL Health Technologies Corp. (TSX: WELL) announced on October 28, 2026, that Canada's Competition Bureau has concluded its review of WELL's acquisition of a controlling interest in HEALWELL and has issued a No Action Letter. The letter, issued on October 22, 2026, confirms that the Commissioner of Competition does not currently intend to challenge the transaction under the Competition Act. The clearance removes a key regulatory uncertainty surrounding the merger and HEALWELL's concurrent acquisition of Orion Health, both of which were completed on April 1, 2025.

Key Points

  • HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) and WELL Health Technologies Corp. (TSX: WELL) jointly announced the regulatory clearance
  • Canada's Competition Bureau issued a No Action Letter on October 22, 2026, concluding its merger review
  • The review covered WELL's acquisition of a majority interest in HEALWELL and HEALWELL's concurrent acquisition of Orion Health, completed April 1, 2025
  • Investors may watch for any operational or strategic developments now that the regulatory review process has concluded

Competition Bureau Issues No Action Letter for WELL–HEALWELL Transaction

The No Action Letter, issued October 22, 2026, confirms that the Commissioner of Competition does not, at this time, intend to make an application under section 92 of the Competition Act regarding WELL's acquisition of a controlling interest in HEALWELL AI. The clearance also covers HEALWELL's concurrent acquisition of Orion Health, completed on April 1, 2025. The Bureau's decision signals that regulators found no current grounds to challenge the transaction on competition grounds, closing a review process that had been active since at least December 2025.

Federal Court Record Production Order Preceded the Bureau's Final Decision

In December 2025, the Competition Bureau announced it had obtained a Federal Court order requiring the production of records and information relating to the transaction. Both HEALWELL and WELL cooperated with the Bureau throughout the review and produced all requested records and information, according to the announcement. The companies' cooperation with the Bureau's formal information-gathering process appears to have supported the timely conclusion of the review, though the release does not specify the duration or scope of documents produced.

HEALWELL's Healthcare AI Strategy Remains the Stated Focus Post-Clearance

HEALWELL AI describes itself as a healthcare artificial intelligence company focused on preventative care, operating in areas including data science, AI-powered patient identification, and clinical decision support. Chairman Hamed Shahbazi stated the company remains focused on executing its strategy and delivering value to healthcare practitioners, patients, and shareholders following the Bureau's conclusion. The release does not disclose any revised financial guidance, updated operational targets, or new strategic initiatives tied specifically to the receipt of the No Action Letter.